Numan's Shift to Continuous Monitoring

This expansion matters because it turns Numan from a prescription seller into a daily monitoring system for long term metabolic care. CGMs, smart scales, and lab panels give Numan more touchpoints between refills, more data to guide coaching, and more items to bill for. That fits the way its weight loss program already works, with recurring subscriptions, scheduled blood tests, clinician review, and app based follow up.

• Numan already has the operating model for this. Its weight loss plans bundle GLP-1s, coaching, clinician messaging, and repeat blood tests every 3 to 6 months, so adding connected devices is a small workflow extension, not a new business line from scratch.
  1 sacra
• Comparable obesity platforms are already moving this way. Yazen connects smart scales and fitness trackers in its app, gives patients blood work before prescribing, and partnered with Withings in February 2026 to use body composition data beyond simple weight tracking.
  3 sacra 6 withings
• The strategic value is differentiation as GLP-1 access gets commoditized. When drug makers and telehealth rivals can all offer the same injections, platforms that show trends in glucose, muscle mass, visceral fat, and lab markers have a stronger case for charging for ongoing care, not just medicine access.
  1 sacra 3 sacra 4 dexcom 5 withings 6 withings

The next phase of obesity telehealth looks more like remote metabolic management than monthly prescription renewal. The winners will be the platforms that combine medication, diagnostics, connected devices, and coaching into one loop, then use that loop to keep patients engaged for years through maintenance, prevention, and broader cardiometabolic care.